公司資料
Adial Pharmaceuticals 股價、新聞與催化劑
- 股票代碼:
- ADIL
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
4.13 USD (+2.99%)
收盤價
最後更新: 2026年10月1日
5.06M USD
市值
股價為何變動
截至 2026年10月1日，ADIL 上漲 2.99%，收於 $4.13。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
Adial Pharmaceuticals is a clinical-stage biotechnology company focused on treatments for alcohol use disorder and related addiction biology. Its story is centered on the difficult intersection of behavioral health, relapse prevention, and chronic disease management.
所在地與產業分類
Adial is headquartered in the United States and listed on NASDAQ, with a small-cap specialty-biopharma profile. It sits in addiction medicine rather than mainstream oncology or immunology.
商業模式特徵
The business depends on clinical progress, regulatory strategy, and the ability to show that its candidate can create a meaningful treatment option in addiction care. Investors usually watch proof-of-concept data, safety, and commercialization potential.
生技產業定位
Adial occupies a niche addiction-medicine position within biotech. The stock is catalyst-sensitive because the company is still trying to prove a focused therapeutic thesis in a difficult indication.
未來催化劑
- Adial’s catalyst is AD04 and the alcohol-use-disorder program, where any clinical or regulatory update can keep the story alive. The company still needs a stronger human signal.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。